Sandoz Nabs FDA Approvals for First Two Biosimilars for Amgen’s Denosumab

The FDA on Tuesday approved two of Sandoz’s biosimilars for Amgen’s blockbuster bone-preserving therapy denosumab, though the Novartis spin-off is keeping mum on its target launch date, pricing and other launch details.